Pathology: mGC or mGEJC - L1 - PDL1 positive;
| mGC or mGEJC - L1 - PDL1 positive | |||||
| KEYNOTE-062 (P vs C ; CPS>10), 2020 | KEYNOTE-062 (P vs C ; CPS>1), 2020 | KEYNOTE-062 (PC vs C ; CPS>10), 2020 | KEYNOTE-062 (PC vs C ; CPS>1), 2020 | ||
| pembrolizumab alone | 2 | T1 | T1 | ||
| pembrolizumab plus SoC | 2 | T1 | T1 | ||
| placebo plus SoC | 0 | T0 | T0 | T0 | |
| Standard of Care (SoC) | 0 | T0 | |||